Surgical revascularization of the celiac artery for persistent intestinal ischemia in short bowel syndrome

Roussel, Arnaud; Nuzzo, Alexandre; Pellenc, Quentin; Castier, Yves; Blic, Romain de; Cerceau, Pierre; Boulitrop, Célia; Coblence, Mathieu; Aguir, Sonia; Mordant, Pierre; Maggiori, Léon; Huguet, Audrey; Sibert, Annie; Joly, Francisca; Corcos, Olivier

doi:10.1016/j.ijsu.2017.12.010

Cited by 5 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the differences observed may have been related to hypofunction of the residual intestine in Crohn's disease or the high volume of intestinal fluid drainage associated with stoma construction. Although mesenteric ischemia is a frequent cause of SBS [23][24][25], in the current studies in Japanese patients, Crohn's disease was the most common cause of SBS. In Crohn's disease, the small bowel function can be impaired even when the length is not affected, due to reasons such as inflammation of stricture in the intestines [26,27].…”

Section: Discussionmentioning

confidence: 53%

Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension

et al. 2022

View full text Add to dashboard Cite

Purpose The short- and long-term efficacy, safety, and pharmacokinetics of teduglutide were analyzed in adult Japanese patients with short bowel syndrome and intestinal failure (SBS-IF). Methods Patients received teduglutide 0.05 mg/kg/day in clinical trials (TED-C14-004, SHP633-306, and extension SHP633-307). Data were analyzed at 24 weeks and an interim data cut-off of 4.5 years. Results The parenteral support (PS) volume decreased by ≥ 20% for 9/18 patients at 24 weeks and in all 11 patients by data cut-off in SHP633-307. The mean (standard deviation) PS volume decreased from baseline at 24 weeks in TED-C14-004 (−30.1 ± 25.9%) and SHP633-306 (−25.6 ± 25.5%), and at data cut-off in SHP633-307 (−57.08 ± 28.49%). Teduglutide was absorbed quickly. The adverse events were consistent with the underlying disease and known adverse drug reactions. Anti-teduglutide antibody titers declined with long-term treatment. Conclusions In Japanese adults with SBS-IF, teduglutide treatment was associated with clinically meaningful reductions in PS requirements, similar to findings in prior international studies. No new safety concerns specific to the Japanese SBS-IF patient population were identified with short- or long-term teduglutide treatment. Anti-teduglutide antibody titers disappeared in most Japanese adults with long-term treatment. These results constitute the longest evaluation of teduglutide treatment within clinical trials reported to date.

show abstract